Chinese Journal of Antituberculosis ›› 2024, Vol. 46 ›› Issue (8): 926-934.doi: 10.19982/j.issn.1000-6621.20240093
• Original Articles • Previous Articles Next Articles
Cai Qinghe, Fu Hui(), Chen Ruiming, Fan Youming, Yang Qingwei
Received:
2024-03-14
Online:
2024-08-10
Published:
2024-08-01
Contact:
Fu Hui
E-mail:fh8959@126.com
CLC Number:
Cai Qinghe, Fu Hui, Chen Ruiming, Fan Youming, Yang Qingwei. Analysis of the clinical characteristics and influencing factors of pulmonary tuberculosis patients with diabetes mellitus in Shantou City from 2016 to 2022[J]. Chinese Journal of Antituberculosis, 2024, 46(8): 926-934. doi: 10.19982/j.issn.1000-6621.20240093
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20240093
特征 | 例数 | 构成比(%) | 特征 | 例数 | 构成比(%) |
---|---|---|---|---|---|
性别 | 年龄组(岁) | ||||
男性 | 15338 | 73.15 | <30 | 3820 | 18.22 |
女性 | 5630 | 26.85 | 30~59 | 9656 | 46.05 |
民族 | 60~95 | 7492 | 35.73 | ||
汉族 | 20855 | 99.46 | 职业 | ||
少数民族 | 113 | 0.54 | 家政 | 9783 | 46.66 |
人口类型 | 农民/渔民/工人 | 7968 | 38.00 | ||
本地人口 | 12556 | 59.88 | 儿童/学生/老师 | 868 | 4.14 |
流动人口 | 8412 | 40.12 | 离退人员 | 404 | 1.93 |
居住地性质 | 商业服务 | 324 | 1.54 | ||
乡村 | 4442 | 21.18 | 管理干部/医务人员 | 150 | 0.71 |
城市 | 16526 | 78.82 | 其他a | 402 | 1.92 |
合并糖尿病 | 不详b | 1069 | 5.10 | ||
是 | 1694 | 8.08 | |||
否 | 19574 | 91.92 | 合计 | 20968 | 100.00 |
特征 | 患者 例数 | 合并糖尿病(1694例) | 未合并糖尿病(19574例) | χ2值 | P值 | ||
---|---|---|---|---|---|---|---|
例数 | 构成比(%) | 例数 | 构成比(%) | ||||
性别 | 24.661 | <0.001 | |||||
男性 | 15338 | 1326 | 8.65 | 14012 | 91.35 | ||
女性 | 5630 | 368 | 6.54 | 5262 | 93.46 | ||
民族 | 6.090 | 0.014 | |||||
汉族 | 20855 | 1692 | 8.11 | 19163 | 91.89 | ||
少数民族 | 113 | 2 | 1.77 | 111 | 98.23 | ||
年龄组(岁) | 402.463 | <0.001 | |||||
<30 | 3820 | 20 | 0.52 | 3800 | 99.48 | ||
30~59 | 9656 | 826 | 8.55 | 8830 | 91.45 | ||
60~95 | 7492 | 848 | 11.32 | 6644 | 88.68 | ||
职业 | 358.725 | <0.001 | |||||
家政 | 9783 | 1046 | 10.69 | 8737 | 89.31 | ||
农民、渔民/工人 | 7968 | 391 | 4.91 | 7577 | 95.09 | ||
儿童/学生/老师 | 868 | 4 | 0.46 | 864 | 99.54 | ||
离退人员 | 404 | 85 | 21.04 | 319 | 78.96 | ||
商业服务 | 324 | 30 | 9.26 | 294 | 90.74 | ||
管理干部/医务人员 | 150 | 14 | 9.33 | 136 | 90.67 | ||
其他a | 402 | 37 | 9.20 | 365 | 90.80 | ||
不详b | 1069 | 87 | 8.14 | 982 | 91.86 | ||
人口类型 | 53.446 | <0.001 | |||||
本地人口 | 12556 | 873 | 6.95 | 11683 | 93.05 | ||
流动人口 | 8412 | 821 | 9.76 | 7591 | 90.24 | ||
居住地性质 | 0.542 | 0.462 | |||||
乡村 | 4442 | 347 | 7.81 | 4095 | 92.19 | ||
城市 | 16526 | 1347 | 8.15 | 15179 | 91.85 | ||
就诊途径 | 45.316 | <0.001 | |||||
因症就诊 | 12503 | 1079 | 8.63 | 11424 | 91.37 | ||
转诊 | 5459 | 338 | 6.19 | 5121 | 93.81 | ||
追踪到位 | 2520 | 247 | 9.80 | 2273 | 90.20 | ||
健康体检 | 58 | 2 | 3.45 | 56 | 96.55 | ||
主动筛查 | 389 | 27 | 6.94 | 362 | 93.06 | ||
其他c | 39 | 1 | 2.56 | 38 | 97.44 | ||
诊断结果 | 313.114 | <0.001 | |||||
病原学阳性 | 9883 | 1147 | 11.61 | 8736 | 88.39 | ||
病原学阴性 | 10842 | 535 | 4.93 | 10307 | 95.07 | ||
无病原学结果 | 243 | 12 | 4.94 | 231 | 95.06 | ||
患者分类 | 42.335 | <0.001 | |||||
初治 | 17528 | 1321 | 7.54 | 16207 | 92.46 | ||
复治 | 3440 | 373 | 10.84 | 3067 | 89.16 | ||
治疗2个月末痰检结果 | 259.304 | <0.001 | |||||
阴性 | 11992 | 708 | 5.90 | 11284 | 94.10 | ||
阳性 | 389 | 90 | 23.14 | 299 | 76.86 | ||
无结果 | 8587 | 896 | 10.43 | 7691 | 89.57 | ||
治疗结果 | 221.180 | <0.001 | |||||
治愈 | 7564 | 828 | 10.95 | 6736 | 89.05 | ||
完成疗程 | 12039 | 691 | 5.74 | 11348 | 94.26 | ||
失败 | 166 | 18 | 10.84 | 148 | 89.16 | ||
失访 | 414 | 65 | 15.70 | 349 | 84.30 | ||
死亡 | 63 | 9 | 14.29 | 54 | 85.71 | ||
其他d | 722 | 83 | 11.50 | 639 | 88.50 | ||
合计 | 20968 | 1694 | 8.08 | 19274 | 91.92 |
年份 | 例数 | 糖尿病 | 年龄组(岁) | 人口类型 | ||||
---|---|---|---|---|---|---|---|---|
合并 | 未合并 | <30 | 30~59 | ≥60 | 本地人口 | 流动人口 | ||
2016 | 3406 | 67(1.97) | 3339(98.03) | 649(19.05) | 1852(54.38) | 905(26.57) | 2966(87.08) | 440(12.92) |
2017 | 2648 | 107(4.04) | 2541(95.96) | 518(19.56) | 1335(50.42) | 795(30.02) | 1989(75.11) | 659(24.89) |
2018 | 3205 | 223(6.96) | 2982(93.04) | 648(20.22) | 1403(43.77) | 1154(36.01) | 1245(38.85) | 1960(61.15) |
2019 | 3284 | 301(9.17) | 2983(90.83) | 620(18.88) | 1382(42.08) | 1282(39.04) | 1008(30.69) | 2276(69.31) |
2020 | 2885 | 291(10.09) | 2594(89.91) | 533(18.47) | 1216(42.15) | 1136(39.38) | 900(31.20) | 1985(68.80) |
2021 | 3348 | 359(10.72) | 2989(89.28) | 556(16.61) | 1492(44.56) | 1300(38.83) | 2299(68.67) | 1049(31.33) |
2022 | 2192 | 346(15.78) | 1846(84.22) | 296(13.50) | 976(44.53) | 920(41.97) | 2149(98.04) | 43(1.96) |
合计 | 20968 | 1694(8.08) | 19274(91.92) | 3820(18.22) | 9656(46.05) | 7492(35.73) | 12556(59.88) | 8412(40.12) |
438.749 | 290.521 | 5483.796 | ||||||
P值 | <0.001 | <0.001 | <0.001 |
变量 | 赋值 |
---|---|
因变量 | 未合并糖尿病=0;合并糖尿病=1 |
职业分类 | 农民/渔民/工人=0;管理干部/医务人员=1;家政=2;离退休人员=3;商业服务=4;儿童/学生/老师=5;其他职业=6;不详=7 |
就诊途径 | 因症就诊=0;转诊=1;追踪到位=2;主动筛查=3;健康体检=4;其他=5 |
治疗结果 | 治愈=0;完成疗程=1;治疗失败=2;死亡=3;失访=4;其他=5 |
出现症状至初诊时间间隔 | 1个月内=0;1~3个月内=1;3~6个月内=2;6~12个月内=3;12个月以上=4 |
病原学分类 | 病原学阴性=0;无病原学结果=1;病原学阳性=2 |
年龄组 | <30岁=0;30~59岁=1;60~95岁=2 |
治疗2个月末痰检结果 | 阴性=0;阳性=1;无结果=2 |
民族 | 汉族=0;少数民族=1 |
人口类型 | 本地人口=0;流动人口=1 |
性别 | 男性=0;女性=1 |
居住地性质 | 乡村=0;城镇=1 |
治疗史 | 初治=0;复治=1 |
因素 | β值 | s | Wald χ2值 | P值 | OR(95%CI)值 |
---|---|---|---|---|---|
女性 | 0.001 | 0.064 | 0.000 | 0.984 | 1.001(0.883~1.135) |
少数民族 | -0.905 | 0.723 | 1.564 | 0.211 | 0.405(0.098~1.670) |
流动人口 | 0.258 | 0.058 | 20.069 | <0.001 | 1.294(1.156~1.449) |
30~59岁 | 2.835 | 0.233 | 147.987 | <0.001 | 17.026(10.783~26.882) |
60~95岁 | 3.043 | 0.235 | 168.371 | <0.001 | 20.966(13.240~33.199) |
管理干部/医务人员 | 0.925 | 0.300 | 9.514 | 0.002 | 2.521(1.401~4.536) |
家政 | 0.664 | 0.066 | 102.496 | <0.001 | 1.943(1.709~2.210) |
离退休人员 | 1.289 | 0.141 | 83.948 | <0.001 | 3.630(2.755~4.783) |
商业服务 | 1.080 | 0.210 | 26.532 | <0.001 | 2.945(1.953~4.442) |
儿童/学生/老师 | -0.428 | 0.522 | 0.674 | 0.412 | 0.652(0.234~1.812) |
其他职业a | 0.850 | 0.189 | 20.307 | <0.001 | 2.340(1.617~3.388) |
职业不详b | 0.919 | 0.130 | 49.956 | <0.001 | 2.506(1.942~3.233) |
转诊 | -0.083 | 0.071 | 1.370 | 0.242 | 0.920(0.801~1.058) |
追踪到位 | 0.469 | 0.085 | 30.613 | <0.001 | 1.598(1.354~1.887) |
主动筛查 | -0.032 | 0.736 | 0.002 | 0.965 | 0.968(0.229~4.097) |
健康体检 | 0.599 | 0.217 | 7.623 | 0.006 | 1.820(1.190~2.783) |
其他就诊方式c | -0.930 | 1.028 | 0.818 | 0.366 | 0.395(0.053~2.961) |
无病原学结果 | -0.109 | 0.305 | 0.128 | 0.720 | 0.896(0.493~1.631) |
病原学阳性 | 0.937 | 0.088 | 114.682 | <0.001 | 2.554(2.151~3.031) |
复治患者 | 0.079 | 0.067 | 1.410 | 0.235 | 1.083(0.950~1.234) |
完成疗程 | -0.015 | 0.087 | 0.031 | 0.860 | 0.985(0.829~1.169) |
治疗失败 | -0.187 | 0.263 | 0.505 | 0.477 | 0.830(0.496~1.389) |
死亡 | 0.173 | 0.375 | 0.212 | 0.645 | 1.189(0.570~2.481) |
失访 | 0.749 | 0.151 | 24.536 | <0.001 | 2.114(1.572~2.843) |
其他治疗结果d | -0.049 | 0.130 | 0.140 | 0.708 | 0.953(0.739~1.229) |
治疗后第2个月末痰检阳性 | 1.000 | 0.135 | 54.786 | <0.001 | 2.717(2.085~3.540) |
治疗后第2个月末痰检无结果 | 0.462 | 0.064 | 51.473 | <0.001 | 1.588(1.399~1.802) |
居住在城镇 | 0.021 | 0.065 | 0.098 | 0.754 | 1.021(0.898~1.160) |
1~3个月内就诊 | 0.207 | 0.059 | 12.125 | <0.001 | 1.229(1.094~1.381) |
3~6个月内就诊 | 0.272 | 0.089 | 9.248 | 0.002 | 1.312(1.101~1.563) |
6~12个月内就诊 | 0.218 | 0.111 | 3.889 | 0.049 | 1.244(1.001~1.544) |
12个月以上就诊 | -0.036 | 0.165 | 0.047 | 0.829 | 0.965(0.699~1.333) |
[1] | World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization, 2023. |
[2] | Al-Rifai RH, Pearson F, Critchley JA, et al. Association between diabetes mellitus and active tuberculosis: A systematic review and meta-analysis. PLoS One, 2017, 12(11):e0187967. doi:10.1371/journal.pone.0187967. |
[3] | Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract, 2022, 183:109119. doi:10.1016/j.diabres.2021.109119. |
[4] | Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Global Health, 2019, 7(4):e448-e460. doi:10.1016/S2214-109X(18)30487-X. |
[5] | Meng F, Lan L, Wu G, et al. Impact of diabetes itself and glycemic control status on tuberculosis. Front Endocrinol (Lausanne), 2023, 14:1250001. doi:10.3389/fendo.2023.1250001. |
[6] | Ssekamatte P, Sande OJ, van Crevel R, et al. Immunologic, metabolic and genetic impact of diabetes on tuberculosis susceptibility. Front Immunol, 2023, 14:1122255. doi:10.3389/fimmu.2023.1122255. |
[7] | Restrepo BI, Schlesinger LS. Impact of diabetes on the natural history of tuberculosis. Diabetes Res Clin Pract, 2014, 106(2):191-199. doi:10.1016/j.diabres.2014.06.011. |
[8] | Harries AD, Kumar AM, Satyanarayana S, et al. Addressing diabetes mellitus as part of the strategy for ending TB. Trans R Soc Trop Med Hyg, 2016, 110: 173-179. doi:10.1093/trstmh/trv111. |
[9] |
Harries AD, Lin Y, Satyanarayanas S, et al. The looming epidemic of diabetes-associated tuberculosis: learning lessons from HIV-associated tuberculosis. Int J Tuberc Lung Dis, 2011, 15: 1436-1444, i. doi:10.5588/ijtld.11.0503.
pmid: 21902876 |
[10] | 中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 2017-11-09. |
[11] | 纪立农, 陈莉明, 郭晓慧, 等. 中国慢性疾病防治基层医生诊疗手册(糖尿病分册)2015年版. 中国糖尿病杂志, 2015, 23(8): 673-701. doi:10.3969/j.issn.1006-6187.2015.08.001. |
[12] | World Health Organization. Treatment of Tuberculosis Guideline for National Program. 4th ed. Geneva: World Health Organization, 2009. |
[13] | World Health Organization. Guidelines for the treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva: World Health Organization, 2017. |
[14] | 中国疾病预防控制中心结核病预防控制中心. 中国结核病防治工作技术指南. 北京: 人民卫生出版社, 2021: 249-250. |
[15] | Lin Y, Harries AD, Kumar AM, et al. Management of diabetes mellitus-tuberculosis: a guide to the essential practice. Paris: International Union Against Tuberculosis and Lung Disease, 2019. https://theunion.org/sites/default/files/2020-11/TheUnion_DMTB_Guide.pdf. |
[16] |
Li L, Lin Y, Mi F, et al. Screening of patients with tuberculosis for diabetes mellitus in China. Trop Med Int Health, 2012, 17(10): 1294-1231. doi:10.1111/j.1365-3156.2012.03068.x.
pmid: 22830945 |
[17] | Lin Y, Li L, Mi F, et al. Screening of patients with diabetes mellitus for tuberculosis in China. Trop Med Int Health, 2012, 17(10): 1302-1308. doi:10.1111/j.1365-3156.2012.03069.x. |
[18] | van Crevel R, Critchley JA. The Interaction of Diabetes and Tuberculosis: Translating Research to Policy and Practice. Trop Med Infect Dis, 2021, 6(1):8. doi:10.3390/tropicalmed6010008. |
[19] |
Adepoju VA, Adepoju OE, Inegbeboh J, et al. Bidirectional Screening for Tuberculosis, Diabetes Mellitus and other Comorbid Conditions in a Resource Constrained Setting: A Pilot Study in Lagos, Nigeria. West Afr J Med, 2022, 39(12):1305-1311.
pmid: 36583949 |
[20] | Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ, 2020, 369:m997. doi:10.1136/bmj.m997. |
[21] | Burke RM, Nliwasa M, Feasey HRA, et al. Community-based active case-finding interventions for tuberculosis: a systematic review. Lancet Public Health, 2021, 6(5):e283-e299. doi:10.1016/S2468-2667(21)00033-5. |
[22] |
van Crevel R, Koesoemadinata R, Hill PC, et al. Clinical management of combined tuberculosis and diabetes. Int J Tuberc Lung Dis, 2018, 22(12):1404-1410. doi:10.5588/ijtld.18.0340.
pmid: 30606312 |
[23] | Wang JY, Lee MC, Shu CC, et al. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months?. Chest, 2015, 147(2):520-528. doi:10.1378/chest.14-0918. |
[1] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[2] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[3] | Zhang Guoqin, Qu Ting, Meng Qinglin, Zhou Lin, Liu Eryong. Implementation update of strategy for the control of tuberculosis and HIV/AIDS co-infection in China [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 12-17. |
[4] | Fan Jun, Wang Heng, Lan Tinglong, Dong Weijie, Tang Kai, Li Yuan, Yan Guangxuan, Xu Shangsheng, Kang Zhigang, Qin Shibing. Clinical characteristics and surgical outcomes of 12 cases of non-tuberculous mycobacterial spondylitis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 87-95. |
[5] | Wang Fei, Hua Duo, Guo Jianjian, Liu Chang, Han Lu, Ren Yi. Characteristic analysis of non-tuberculous mycobacterial pulmonary disease patients in Wuhan area from 2021 to 2023 [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1069-1076. |
[6] | Palidanguli Abudureheman, Wang Senlu, Gulina Badeerhan, Wang Le, Zulikatiayi Abudula, Wang Xinqi, Maiwulajiang Yimamu, Wang Xijiang. Distribution of Mycobacterium tuberculosis genotypes in Kashgar region and their association with clinical characteristics of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1077-1082. |
[7] | Huang Tao, Jian Huiyong, Wang Xinqi, Liu Nianqiang, Yipar Aihaiti, Wang Mingzhe, Jiayinati Jingesi, Wang Senlu. Analysis of influencing factors of treatment outcomes in patients with pulmonary tuberculosis complicated with diabetes mellitus in Xinjiang Uygur Autonomous Region [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1083-1088. |
[8] | Yang Liangzi, Zhang Peize, Lu Shuihua. Interpretation of World Health Organization’s Co-administration of Treatment for Drug-resistant Tuberculosis and Hepatitis C: 2024 Update [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 874-876. |
[9] | Liu Ling, Zeng Yi, Wang Jin, Liu Xiaoling, Liu Yan, Lin Feishen, Guo Jing. Construction and evaluation of a model for predicting malnutrition in patients with pulmonary tuberculosis and diabetes mellitus [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 903-909. |
[10] | Jiang Bijia, Chen Cheng, Zhou Jinyi, Zhu Limei, Su Jian, Lu Wei. Analysis of tuberculosis incidence and influencing factors in type 2 diabetic patients in community [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 951-957. |
[11] | Chai Dongyu, Qin Shuyi, Zhang Ronghua, Zou Nannan, Wang Xin. Analysis of risk factors for viral pneumonia combined with invasive pulmonary mycosis [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 750-755. |
[12] | Fu Keyan, Zhu Bangzheng, Ye Jian. Research progress on interstitial lung disease combined with Mycobacterium tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 823-829. |
[13] | Liu Guizhen, Deng Guofang. Interpretation of Evidence and research gaps identified during development of policy guidelines for tuberculosis (Second edition): tuberculosis related comorbidity [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 618-624. |
[14] | Li Yao, Fang Zhe, Luo Danlin, Hu Yanmei, Tang Mi, Tang Zhigang, Wen Xinmin, Zhang Yong, Yao Bibo, Wang Qi, Yi Hengzhong. Clinical characteristics and prognosis of patients with novel coronavirus infection complicated with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 687-698. |
[15] | Yang Rui, Li Ling, Chen Jinou, Xu Lin. Analysis of influencing factors of anti-tuberculosis treatment effect for pulmonary tuberculosis patients complicated with diabetes in Yunnan Province from 2017 to 2021 [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 519-524. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||